Marked Impairment of Protease-Activated Receptor Type 1-Mediated Vasodilation and Fibrinolysis in Cigarette Smokers. Smoking, Thrombin, and Vascular Responses In Vivo

Journal of the American College of Cardiology

Volumn 52, Issue 1, 2008, Pages 33-39

  Lang, Ninian N ^a   Gumundsdóttir, Ingibjörg J ^a   Boon, Nicholas A ^b   Ludlam, Christopher A ^a   Fox, Keith A ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

blood flow; endothelium; fibrinolysis; smoking; thrombosis

Indexed keywords

BRADYKININ; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE ACTIVATED RECEPTOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGONIST; ARTICLE; ATHEROGENESIS; CIGARETTE SMOKING; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; FEMALE; FOREARM BLOOD FLOW; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING; THROMBOGENESIS; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; BIOLOGICAL MARKERS; BRADYKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; FOREARM; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; NITROPRUSSIDE; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLETHYSMOGRAPHY; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; RESEARCH DESIGN; RISK FACTORS; SMOKING; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; VASODILATION; VASODILATOR AGENTS;

EID: 45549104238     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.04.003     Document Type: Article

References (25)

1. Ambrose J.A., and Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43 (2004) 1731-1737
2. Teo K.K., Ounpuu S., Hawken S., et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368 (2006) 647-658
3. Zieske A.W., McMahan C.A., McGill Jr. H.C., et al. Smoking is associated with advanced coronary atherosclerosis in youth. Atherosclerosis 180 (2005) 87-92
4. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., and Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 336 (1997) 1276-1282
5. Davies M.J., Woolf N., Rowles P.M., and Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J 60 (1988) 459-464
6. Oliver J.J., Webb D.J., and Newby D.E. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 25 (2005) 2470-2479
7. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., and Miller G.J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342 (1993) 1076-1079
8. Jansson J.H., Olofsson B.O., and Nilsson T.K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 88 (1993) 2030-2034
9. Nordenhem A., Leander K., Hallqvist J., de Faire U., Sten-Linder M., and Wiman B. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. Thromb Res 116 (2005) 223-232
10. Fox K., Robison A., Knabb R., Rosamond T., Sobel B., and Bergmann S. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 72 (1985) 1346-1354
11. Robinson S.D., Ludlam C.A., Boon N.A., and Newby D.E. Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 27 (2007) 1651-1656
12. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 407 (2000) 258-264
13. Hollenberg M.D., and Compton S.J. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54 (2002) 203-217
14. Gumundsdóttir I.J., Megson I.L., Kell J.S., et al. Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans. Circulation 114 (2006) 1625-1632
15. Newby D.E., Wright R.A., Labinjoh C., et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99 (1999) 1411-1415
16. Pretorius M., Rosenbaum D.A., Lefebvre J., Vaughan D.E., and Brown N.J. Smoking impairs bradykinin-stimulated t-PA release. Hypertension 39 (2002) 767-771
17. Newby D.E., McLeod A.L., Uren N.G., et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 103 (2001) 1936-1941
18. Takashima H., Matsumoto T., Nakae I., Yamane T., and Horie M. Cigarette smoking impairs bradykinin-stimulated tissue plasminogen activator release in human coronary circulation. Thromb Res 120 (2007) 791-796
19. Newby D.E., Wright R.A., Ludlam C.A., Fox K.A., Boon N.A., and Webb D.J. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost 78 (1997) 1242-1248
20. Brown N.J., Gainer J.V., Stein C.M., and Vaughan D.E. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 33 (1999) 1431-1435
21. Seiffert D., Ciambrone G., Wagner N., Binder B., and Loskutoff D. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 269 (1994) 2659-2666
22. Gumundsdóttir I.J., Lang N.L., Boon N.A., et al. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J Am Coll Cardiol 51 (2008) 1749-1756
23. Hoffmeister H., Jur M., Wendel H., Heller W., and Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation 91 (1995) 2520-2527
24. Kiowski W., Linder L., Stoschitzky K., et al. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 90 (1994) 27-34
25. Puranik R., and Celermajer D.S. Smoking and endothelial function. Prog Cardiovasc Dis 45 (2003) 443-458